<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-JOZ5QIF7</identifier><date>2018</date><creator>Grošelj, Aleš</creator><relation>documents/doc/J/URN_NBN_SI_doc-JOZ5QIF7_001.pdf</relation><relation>documents/doc/J/URN_NBN_SI_doc-JOZ5QIF7_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 21</format><identifier identifier_type="COBISSID_HOST">5370796</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-JOZ5QIF7</identifier><language>eng</language><publisher>Institute of Oncology</publisher><source>Book of abstracts</source><rights>InC</rights><subject language_type_id="eng">bleomycin</subject><subject language_type_id="slv">elektrokemoterapija</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="eng">pharmacology</subject><subject language_type_id="slv">strostniki</subject><subject language_type_id="slv">tumorji</subject><title>Pharmacology of bleomycin, implications in lowering the dose</title></Record>